Share

March 2018; 5 (2) ArticleOpen Access

Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod

Maryam Nakhaei-Nejad, David Barilla, Chieh-Hsin Lee, Gregg Blevins, Fabrizio Giuliani
First published December 28, 2017, DOI: https://doi.org/10.1212/NXI.0000000000000432
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1576

Share

This article has a correction. Please see:

Article Information

vol. 5 no. 2 e432
DOI: 
https://doi.org/10.1212/NXI.0000000000000432
PubMed: 
29296636
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received August 17, 2017
  • Accepted in final form October 3, 2017
  • First Published December 28, 2017.
Copyright & Usage: 
Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Maryam Nakhaei-Nejad, PhD,
    2. David Barilla, Dip,
    3. Chieh-Hsin Lee, BSc,
    4. Gregg Blevins, MD and
    5. Fabrizio Giuliani, MD
  1. Maryam Nakhaei-Nejad, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. David Barilla, Dip,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Chieh-Hsin Lee, BSc,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Gregg Blevins, MD and
    5. Scientific Advisory Boards:

    1. Served on Advisory boards for Biogen Idec, Teva Pharmaceuticals, Novartis, Genzyme, Roche and EMD Serono/Merck from 2006-present

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Received travel funding through Biogen Idec, Teva Pharmaceuticals, Novartis, Genzyme, Roche and EMD Serono/Merck from 2006-present

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Self-employed

    Consultancies:

    1. Have received consulting fees from Biogen Idec, Teva Pharmaceuticals, Novartis, Genzyme, Roche and EMD Serono/Merck from 2006-present

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Canadian Institute for Health Research, Alberta Innovates, Canadian Foundation for Innovation

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Multiple Sclerosis Society of Canada

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Fabrizio Giuliani, MD
    6. Scientific Advisory Boards:

    1. (1)Alberta MS Network (non-profit)

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1)Merck-Serono, honoraria (2)Biogen, honoraria (3)Genzyme, honoraria (4)Roche, honoraria

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1)Merck-Serono (2)Biogen (3)Genzyme (4)Roche

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1)Biogen Canada

    Research Support, Government Entities:

    1. (1)Alberta Ministry of Innovation and Advanced Education,AE-2014-0065, Principal Investigator,4 years

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Division of Neurology, Department of Medicine, University of Alberta, Edmonton, Canada.
  1. Correspondence to Dr. Giuliani: fabrizio.giuliani{at}ualberta.ca
View Full Text

Article usage

Article usage: December 2017 to August 2023

AbstractFullPdfSource
Dec 201706313Highwire
Jan 20180870168Highwire
Feb 2018024268Highwire
Mar 201801009108Highwire
Apr 2018030528Highwire
Apr 2018217888pmc
May 2018013641Highwire
Jun 201809222Highwire
Jun 2018235166pmc
Jul 201807617Highwire
Aug 2018113410Highwire
Aug 2018136775pmc
Sep 2018011525Highwire
Oct 2018012215Highwire
Nov 2018017816Highwire
Dec 201802485Highwire
Jan 201921929Highwire
Feb 2019690612Highwire
Mar 20191515233Highwire
Apr 201976732Highwire
May 201947515Highwire
Jun 201959713Highwire
Jul 201937311Highwire
Aug 2019110718Highwire
Sep 201934314Highwire
Oct 201947011Highwire
Nov 201926016Highwire
Dec 201936715Highwire
Jan 202066013Highwire
Feb 202074912Highwire
Mar 202035610Highwire
Apr 20205588Highwire
May 202016614Highwire
Jun 202034010Highwire
Jul 202003910Highwire
Aug 202015315Highwire
Sep 202084337Highwire
Oct 202054914Highwire
Nov 202033815Highwire
Dec 20206217Highwire
Jan 202122713Highwire
Feb 20210234Highwire
Mar 202133315Highwire
Apr 202110338Highwire
May 202133311Highwire
Jun 202134513Highwire
Jul 202144217Highwire
Aug 202154712Highwire
Sep 202143516Highwire
Oct 2021114329Highwire
Nov 202153926Highwire
Dec 202152313Highwire
Jan 202253322Highwire
Feb 202292210Highwire
Mar 202222415Highwire
Apr 20221198Highwire
May 202223215Highwire
Jun 202293310Highwire
Jul 202221127Highwire
Aug 20226409Highwire
Sep 2022104820Highwire
Oct 202244214Highwire
Nov 202276732Highwire
Dec 202252513Highwire
Jan 202344811Highwire
Feb 202384114Highwire
Mar 20231378Highwire
Apr 202322211Highwire
May 202352617Highwire
Jun 20232146Highwire
Jul 202321813Highwire
Aug 202371215Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me

Recommended articles